This week, a group of pharmaceutical companies spent huge sums of money to launch large-scale mergers and acquisitions!

In recent years, in order to cope with the imminent expiration of original research drugs, patent cliffs, intensified industry competition, and declining profits of generic drugs, major pharmaceutical companies have all started the "buy, buy, buy" model
.
At present, less than a month into 2022, in fact, many pharmaceutical companies have issued acquisition announcements
.
It is worth mentioning that this week, a number of pharmaceutical companies have launched acquisitions with huge sums of money
.
UCB to acquire Zogenix for $1.
9 billion In January, UCB and Zogenix announced that they had reached an agreement
.
According to the agreement, UCB will acquire Zogenix, and the total value of this transaction may be as high as about 1.
9 billion US dollars
.
It is reported that the latter is a global biopharmaceutical company dedicated to the development and commercialization of rare disease treatments
.
The industry believes that the acquisition of Zogenix is ​​a complement to UCB's existing therapeutic products
.
It will bring an already-approved drug to UCB for the treatment of life-threatening, rare infant and childhood-onset seizures
.
It is understood that through this transaction, UCB will add Fintepla, a treatment for epilepsy, to its existing product line
.
According to the data, Fintepla has previously been approved by the US FDA and the European Medicines Agency (EMA) and is undergoing regulatory review in Japan for the treatment of patients 2 years of age and older with Dravet syndrome-related seizures
.
Cosette Pharmaceuticals Acquires Eight Cardiovascular Drugs from Daiichi Sankyo Recently, New Jersey-based Cosette Pharmaceuticals also announced that it will acquire the U.
S.
rights to eight cardiovascular drugs from Daiichi Sankyo
.
It is understood that Cosette is a manufacturer of dermatological products with high-quality production facilities for the manufacture of various pharmaceutical dosage forms such as suppositories, creams, ointments, liquids and gels, and is used in the treatment of dermatological and allergic diseases.
The field has an active R&D pipeline
.
Currently, the company is gearing up to diversify
.
It is reported that when Daiichi Sankyo sold multiple drugs this time, in order to change the company structure to one that mainly focuses on patented drugs, the focus will be on oncology investment product portfolio.

.
And Cosette is meant to have a launch pad for future portfolio expansion and growth
.
Cosette is a manufacturer of dermatological products with high-quality production facilities for the manufacture of various pharmaceutical dosage forms such as suppositories, creams, ointments, liquids and gels, and is active in the field of dermatology and the treatment of allergic diseases R&D pipeline
.
Currently, the company is gearing up to diversify
.
The acquisition of U.
S.
sales and distribution rights for eight cardiovascular drugs will serve as a launch pad for future portfolio expansion and growth
.
Shangco Announces Acquisition of 51% Equity of Xiangpeng Youkang On January 18, Shangco announced that it signed an equity transfer agreement with Xiangpeng Youkang shareholders to acquire 51% of its equity
.
Pursuant to the agreement, the total purchase price for the acquisition is approximately $5.
6 million, to be paid for 700,551 shares of the company's restricted common stock at $8 per share
.
According to public information, Xiangpeng Youkang is a comprehensive medical and health service company with a self-developed "Ekang International Medical and Health Service Platform", which is committed to providing users with professional, Fast and effective health management services and one-stop medical service solutions
.